The government has decided to ease its ban on the export
of hydroxychloroquine, a drug that has garnered global interest in the
treatment and prevention of COVID-19.
Background
US President Donald Trump tweeted about “retaliation” if India did
not heed his request for the drug. India said it would supply to
countries that needed it the most, and to neighbours who were dependent on
India’s capabilities.
Details
Ø It is an
antimalarial drug option, considered less toxic than chloroquine, and
prescribed in certain cases. Doctors also prescribe hydroxychloroquine for
patients of rheumatoid arthritis and lupus.
Ø Hydroxychloroquine
had a market size of only around Rs 152.80 crore in the 12 months ended
February 2020. However, several countries source the drug from India.
Ø In a study
last month in the International Journal of Antimicrobial Agents (IJAA), French
scientists reported that the patients treated with the drug showed a
significant reduction of the viral carriage compared to controls, and much
lower average carrying duration than reported of untreated patients.
Azithromycin (an antibiotic) added to hydroxychloroquine was significantly more
efficient for virus elimination.
Ø The Indian
Council of Medical Research (ICMR) had issued an advisory recommending the use
of hydroxychloroquine in asymptomatic healthcare workers treating COVID-19
patients, and also allowed doctors to prescribe it for household contacts of
confirmed COVID-19 patients.
Ø Large
trials are under way on the effectiveness of hydroxychloroquine, and even
chloroquine, in COVID-19 treatment. In the World Health Organization (WHO)
solidarity trial, of which India is a part, clinicians worldwide are to follow
a common protocol to treat patients with hydroxychloroquine.
Comments
Post a Comment